VolitionRx Ltd. Enters and Terminates Material Agreements

Ticker: VNRX · Form: 8-K · Filed: Apr 22, 2025 · CIK: 93314

Sentiment: mixed

Topics: material-agreement, termination, corporate-action

Related Tickers: VNRX

TL;DR

VNRX entered AND terminated a big deal on 4/22 - what's next?

AI Summary

On April 22, 2025, VolitionRx Limited entered into a material definitive agreement and also terminated a material definitive agreement. The company, incorporated in Delaware, operates in the in vitro & in vivo diagnostic substances sector.

Why It Matters

The simultaneous entry into and termination of material definitive agreements suggests a significant shift in the company's strategic partnerships or operational plans, which could impact its future business direction.

Risk Assessment

Risk Level: medium — The simultaneous entry into and termination of material definitive agreements indicates potential instability or significant strategic changes that could pose risks to the company's operations and financial performance.

Key Players & Entities

FAQ

What was the nature of the material definitive agreement entered into by VolitionRx Limited?

The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.

What was the reason for the termination of the material definitive agreement?

The filing states that a material definitive agreement was terminated, but the reasons for this termination are not detailed in the provided text.

When did VolitionRx Limited file this Form 8-K?

VolitionRx Limited filed this Form 8-K on April 22, 2025.

What industry does VolitionRx Limited operate in?

VolitionRx Limited operates in the 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' sector, with SIC code 2835.

What is VolitionRx Limited's principal executive office address?

VolitionRx Limited's principal executive offices are located at 1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 22, 2025 regarding VOLITIONRX LTD (VNRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing